tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MEOBF Stock Latest News

Mesoblast to Present Half-Year Results as It Expands Global Cell Therapy Portfolio
Company AnnouncementsMesoblast to Present Half-Year Results as It Expands Global Cell Therapy Portfolio
2d ago
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
25d ago
GDS
MMM
Mesoblast’s Ryoncil Shows Strong Early Survival in Real-World Use as U.S. Rollout Expands
PremiumCompany Announcements
Mesoblast’s Ryoncil Shows Strong Early Survival in Real-World Use as U.S. Rollout Expands
26d ago
JPMorgan Ceases to Be Substantial Holder in Mesoblast
PremiumCompany Announcements
JPMorgan Ceases to Be Substantial Holder in Mesoblast
27d ago
Mesoblast received FDA feedback on potential BLA for rexlemestrocel-L
PremiumThe Fly
Mesoblast received FDA feedback on potential BLA for rexlemestrocel-L
1M ago
MESO
FDA Feedback Boosts Mesoblast’s Rexlemestrocel‑L Bid in Chronic Low Back Pain
PremiumCompany AnnouncementsFDA Feedback Boosts Mesoblast’s Rexlemestrocel‑L Bid in Chronic Low Back Pain
1M ago
Mesoblast Issues 6.9 Million New Shares Following Conversion of Unquoted Securities
Premium
Company Announcements
Mesoblast Issues 6.9 Million New Shares Following Conversion of Unquoted Securities
1M ago
Mesoblast Seeks ASX Quotation for 7.3 Million New Shares from Employee Scheme
Premium
Company Announcements
Mesoblast Seeks ASX Quotation for 7.3 Million New Shares from Employee Scheme
1M ago
Mesoblast Director Eric Rose Increases Shareholding Through Option Exercise
PremiumCompany Announcements
Mesoblast Director Eric Rose Increases Shareholding Through Option Exercise
1M ago
Mesoblast Director Lyn Cobley Increases On-Market Shareholding
PremiumCompany Announcements
Mesoblast Director Lyn Cobley Increases On-Market Shareholding
1M ago
Mesoblast Boosts Ryoncil Sales 60% and Secures Cheaper US$125m Financing
PremiumCompany Announcements
Mesoblast Boosts Ryoncil Sales 60% and Secures Cheaper US$125m Financing
1M ago
Mesoblast Director’s Warrant Lapse Trims Derivative Exposure Without Dilution
PremiumCompany Announcements
Mesoblast Director’s Warrant Lapse Trims Derivative Exposure Without Dilution
2M ago
Mesoblast Warrants Lapse as Conditions for Conversion Go Unsatisfied
PremiumCompany AnnouncementsMesoblast Warrants Lapse as Conditions for Conversion Go Unsatisfied
2M ago
Mesoblast chair Jane Bell to transition out of role, Philip Facchina to succeed
Premium
The Fly
Mesoblast chair Jane Bell to transition out of role, Philip Facchina to succeed
2M ago
MESO
Mesoblast Reshapes Board Leadership as It Deepens Commercial Focus
Premium
Company Announcements
Mesoblast Reshapes Board Leadership as It Deepens Commercial Focus
2M ago
Mesoblast to Release 10.2 Million Shares From Voluntary Escrow
PremiumCompany Announcements
Mesoblast to Release 10.2 Million Shares From Voluntary Escrow
2M ago
Mesoblast Plans New Issue of 3.2 Million Warrants on ASX
PremiumCompany Announcements
Mesoblast Plans New Issue of 3.2 Million Warrants on ASX
2M ago
Mesoblast Cuts Cost of Capital With New US$125m Non‑Dilutive Credit Line
PremiumCompany Announcements
Mesoblast Cuts Cost of Capital With New US$125m Non‑Dilutive Credit Line
2M ago
Mesoblast Director Boosts Equity Exposure Through New Warrants Linked to Convertible Note Facility
PremiumCompany Announcements
Mesoblast Director Boosts Equity Exposure Through New Warrants Linked to Convertible Note Facility
2M ago
Mesoblast Issues Warrants to Secure $50 Million in Funding
PremiumCompany AnnouncementsMesoblast Issues Warrants to Secure $50 Million in Funding
2M ago
Mesoblast’s Remestemcel-L Outperforms Ruxolitinib in SR-aGvHD Treatment
Premium
Company Announcements
Mesoblast’s Remestemcel-L Outperforms Ruxolitinib in SR-aGvHD Treatment
2M ago
State Street Ceases Substantial Holding in Mesoblast
Premium
Company Announcements
State Street Ceases Substantial Holding in Mesoblast
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >